EGAGenomicsTranscriptome Analysishttps://ega-archive.org/studies/EGAS00001000382EGAEGA study EGAS00001000382Transcriptional profiling of tauopathies in human IPS-derived neurons (2019-08-21)EGArestrictedINO1, ichthyosis-prematurity syndrome, human being, Nerve Cells, Man (Taxonomy), IPS, Modern, Nerve, ino1-B, isyna1, ichthyosis congenita IV, IPS-1, Nerve., human, Cell, Human, FATP4, Homo sapiens, INOS, Tauopathy, Modern Man, ips, ichthyosis congenita 4, Cells, ACSVL4, Neuron, ino1-a, ino1, IPS 1, inos, Nerve Cell, ManPilot, Ribonucleic, Biological Markers, Viral Marker, Materials, Surrogate Endpoints, PhrB photolyase activity, HSN1E, determination, Laboratory, IPS, ino1-B, Biochemical, Gene Expression Profile, Neurologic Diseases, Endpoint, Profiles, Neurologic Degenerative Condition, Serum, pigmented epithelium, "Neurodegenerative disease" EXACT [NCI2004_11_17:C4802], Long Term, Mutations, Publication., Laboratory Markers, Background, Tier, diseases, Neurologic Disorders, Biological, DDPAC, ips, Project, diseases and disorders, 3, synganglion, NUP96, Effect, epithelium, Non Polyadenylated, RNA Gene Products, Animalia, Nervous System Degenerative Diseases, human disease, Degenerative Condition, reference sample, pigmented retina, isyna1, suprasegmental levels of nervous system, Neurodegenerative Disorder, Signatures, MGC138549, DNA cyclobutane dipyrimidine photolyase activity, SUPPRESSOR OF AUXIN RESISTANCE 3, Pilot Project, Immune, Markers, PHF-tau, Degenerative Neurologic Disease, Expression Signature, Viral Markers, PPP1R103, Transcriptomes, Neurologic Degenerative Disease, Homo sapiens disease, Nerve Cell, CXXC finger protein 9, Long-Term Effects, AI413597, Neuro-degenerative disease, PRE, G protein beta1/gamma2 subunit-interacting factor 1, suprasegmental structures, ichthyosis-prematurity syndrome, Viral, Surrogate Endpoint, ribose nucleic acid, Mtapt, animalia, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, Expression Profiles, ribonucleic acids, Longterm Effect, Biochemical Markers, IPS-1, Biologic Marker, Gene Expression, retinal pigment, Marker, Tauopathy, AI551861, ichthyosis congenita 4, Ribonukleinsaeure, Expression Signatures, dipyrimidine photolyase (photosensitive), pentosenucleic acids, Genetic Materials, MSTD, Progressive neurodegenerative disorder, Ribonucleic acids, Expression Profile, MAPT, retinal pigment layer, Genetic Material, Transcriptome Profiles, Acid, ADCADN, Nerve Cells, whole organism, Projects, UNQ203/PRO229, End Points, Degenerative Diseases, DNA (cytosine-5-)-methyltransferase 1, Encephalon, INSDC_feature:gene, FTDP-17, Immunologic, Neurologic Disease, Laboratory Marker, Neurodegenerative disease, TAU_HUMAN, disease, phr A photolyase activity, DNA-photoreactivating enzyme, Material, Biochemical Marker, Degenerative, Cells, Koerper, Pilot Study, ACSVL4, MAPTL, Cistron, ino1-a, the brain, other disease, Genetic Backgrounds, paired helical filament-tau, Effects, Transcriptome Profile, Clinical Markers, Clinical Marker, Nerve, Degenerative Neurologic Disorders, Gene, photoreactivating enzyme activity, cerebral degeneration disease, AW045860, Surrogate End Points, Surrogate Markers, Aim, AIM, Publication, Studies, Gene Products, disease or disorder, stratum pigmentosa retinae, Animal, IPS 1, Backgrounds, study, DNMT1, Biomarker, Nervous System, tau Protein, anatomical systems, MOS3, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, Genetic, Clinical, DNMT1_HUMAN, PRECOCIOUS, Longterm, Profile, Biological Marker, F23A5.3, metazoa, Long-Term, CK1epsilon, Neurodegenerative Disorders, non-neoplastic, Non-Polyadenylated RNA, Study, AW457082, API6, Neurologic, FATP4, Immunologic Markers, AI426939, Neurologic Degenerative Diseases, Degenerative Neurologic Diseases, KC1epsilon, disorder, Neuron, Long-Term Effect, Spinal Cord, Immunologic Marker, MTBT1, F23A5_3, MTBT2, Biologic, Controlled, DNA MTase HsaI, DNA (cytosine-5)-methyltransferase 1, RNA, Controlling, INO1, Neurologic Disorder, Transcriptome, Tau, TAU, FLJ31424, body, Proteins, Serum Markers, disorders, DNMT, PPND, End Point, whole body, RNS, medical condition, neurofibrillary tangle protein, MCMT, Cistrons, encephalon, Cell, Immune Marker, Degenerative Neurologic Disorder, MODIFIER OF SNC1, tau, Surrogate End Point, yeast nucleic acid, DNA methyltransferase HsaI, Protein, Long Term Effects, Gene Expression Signatures, Metazoa, chemical analysis, deoxyribonucleic photolyase activity, condition, Gene Expression Signature, ino1, CKIe, Biologic Markers, CXXC9, ribonucleic acid, tauopathy, Degenerative Conditions, Serum Marker, RPE, CT-2, photolyase activity, Surrogate, Non Polyadenylated RNA, Endpoints, Non-Polyadenylated, microtubule-associated protein tau, ichthyosis congenita IV, Neurologic Degenerative Conditions, Ribonucleic Acid, CXXC-type zinc finger protein 9, Surrogate Marker, Longterm Effects, p. pigmentosa retinae, INOS, Gene Expression Profiles, Neurodegenerative Disease, Central Nervous System, deoxyribonucleate pyrimidine dimer lyase (photosensitive), assay, Signature, inos, CLEC2C, Pilot Studies, m.HsaI, Immune MarkersfalseTranscriptional profiling of tauopathies in human IPS derived neuronsThis project is a pilot study, in collaboration with Maria Grazia Spillantini and Mariangela Iovino (Cambridge Centre for Brain Repair), to investigate the utility of IPS-derived neurons for the study of neurodegenerative disorders. Our aim is to characterise the transcriptional consequences of tauopathies using neurons derived from differentiated IPSCs as a model system. We will use IPS cells derived from six individuals, four with known mutations in the tau protein, 2 without. RNA will be extracted at Day 0 and Day 65 of differentiation by which time the neuronal tauopathy is apparent. RNA will be extracted and the transcriptome of each line characterised using RNAseq. We will then search for genes that are differentially expressed between the transcriptomes of individuals with tau mutations versus those in controls. My lab will analyse the RNAseq data, comparing both affected and controls and both time-points, to establish candidate genes. Darren Logan’s lab, along with our collaborators, will experimentally verify and further investigate these genes in additional lines and animal models. From this analysis we will generate a list of candidate genes that are differentially expressed between cases and controls. This study will not only help us understand the molecular basis of tauopathies, but also identify gene candidates for biomarkers of neurodegenerative disease. It will serve as a proof of principle for future planned studies into generating and transcriptomically analysing an allelic series of Tau mutations in IPSCs with a controlled genetic background. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/2020-07-16 15:33:08EGAS000010003829606EGAD00001005277EGAC00001000205